EXPO trades 14.3% above Wall Street's consensus target of $72.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes EXPO achieves its forward estimates and maintains a stable P/E multiple of 40.9x. This scenario reflects the blended consensus of 8 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, Exponent, Inc. (EXPO) has a Wall Street consensus price target of $72.00, based on estimates from 8 covering analysts. With the stock currently trading at $84.02, this represents a potential downside of -14.3%. The company has a market capitalization of $4.08B.
Analyst price targets range from a low of $72.00 to a high of $72.00, representing a 0% spread in expectations. The median target of $72.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, EXPO trades at a trailing P/E of 35.5x and forward P/E of 40.9x. The forward PEG ratio of 6.86 reflects a premium valuation. Analysts expect EPS to grow -9.9% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $105.50, with bear and bull scenarios of $66.46 and $139.01 respectively. Model confidence stands at 47/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 ICFIICF International, Inc. | $1.4B | $79.68 | $110.00 | +38.1% | Buy | 11.2x | 13 |
 CRAICRA International, Inc. | $1.3B | $197.66 | $194.00 | -1.9% | Buy | 24.0x | 1 |
 HCIHCI Group, Inc. | $2.4B | $186.03 | $230.00 | +23.6% | Buy | 8.9x | 14 |
 FORRForrester Research, Inc. | $171M | $8.83 | — | — | Hold | 11.1x | 4 |
 FCNFTI Consulting, Inc. | $5.4B | $195.71 | $163.50 | -16.5% | Buy | 19.9x | 13 |
 VRSKVerisk Analytics, Inc. | $26.6B | $204.59 | $222.86 | +8.9% | Hold | 26.5x | 25 |
 EFXEquifax Inc. | $22.3B | $189.59 | $197.71 | +4.3% | Buy | 22.3x | 36 |
 ACNAccenture plc | $159.4B | $260.50 | $230.05 | -11.7% | Buy | 18.8x | 53 |
 BAHBooz Allen Hamilton Holding Corporation | $10.3B | $85.35 | $92.00 | +7.8% | Buy | 14.0x | 23 |
 SAICScience Applications International Corporation | $6.2B | $146.30 | $118.75 | -18.8% | Hold | 14.5x | 18 |
Quick answers to the most common questions about buying EXPO stock.
EXPO's consensus price target is $72, -14.3% below the current price of $84.02. The 8 analysts tracking EXPO see downside risk at present valuations.
EXPO has a consensus rating of "Buy" based on 8 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $72 implies -14.3% downside from current levels.
At a forward P/E of 40.8817x, EXPO trades at a premium valuation. The consensus price target of $72 (-14.3% downside) suggests analysts may view current valuations as stretched.
The most bullish Wall Street analyst has a price target of $72 for EXPO, while the most conservative target is $72. The consensus of $72 represents the median expectation. Our quantitative valuation model projects a bull case target of $139 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
EXPO is moderately covered, with 8 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 2 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month EXPO stock forecast based on 8 Wall Street analysts shows a consensus price target of $72, with estimates ranging from $72 (bear case) to $72 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $106, with bear/bull scenarios of $66/$139.
Our quantitative valuation model calculates EXPO's fair value at $106 (base case), with a bear case of $66 and bull case of $139. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 47/100.
EXPO trades at a forward P/E ratio of 40.9x based on next-twelve-months earnings estimates compared to a trailing P/E of 35.5x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Analysts are cautious on EXPO, with 0 Sell ratings and a price target of $72 (-14.3% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
EXPO analyst price targets range from $72 to $72, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $72 consensus represents the middle ground. Our model's $66-$139 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.